The safety and efficacy of anti - PD - 1 and anti - PD - L1 antibodies in HIV - infected individuals with cancer have been examined in two prospective trials thus far (19, 20), and other retrospective and case series have corroborated (21, 22). The gene discussed is RPL17; the disease is cancer.